Is a Zilver stent Drug-eluting stent?
The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding stent made of nitinol and coated with the drug paclitaxel. It is a flexible, slotted tube that is designed to provide support while maintaining flexibility in the vessel upon deployment.
What is Eluvia stent?
The Eluvia Stent was designed and engineered to solve the unique challenge of restenosis in the SFA. Eluvia’s unique polymer-based technology is designed to sustain drug release to match restenosis in the SFA.
What is Zilver stent?
DEVICE DESCRIPTION. The Zilver® Vascular Stent is a self-expanding stent made of nitinol. It is a flexible, slotted tube that is designed to provide support while maintaining flexibility in the vessel upon deployment.
How do you deploy an Eluvia stent?
Roll the thumbwheel of the deployment handle in the direction of the arrow indicated on the handle. Continue to roll thumbwheel until the middle shaft radiopaque marker band passes the distal stent radiopaque markers. Watch for the distal stent radiopaque markers to begin separating as stent starts deploying.
What is ISR in angiogram?
Definition. The definition of ISR remains an angiographic one: namely, recurrent diameter stenosis >50% at the stent segment or its edges (5-mm segments adjacent to the stent) 41, 42. Angiography not only allows determination of ISR severity but also its morphological pattern.
What causes ISR?
The mechanism of ISR is multifactorial, including biological, mechanical, patient, and operator-related factors. The main mechanical contributors are stent underexpansion or fracture, while biological factors include local inflammation leading to aggressive neointimal proliferation and late neoatherosclerosis.
Can you 3D print Nitinol?
So far, CSIRO has proven that it is possible to 3D print self-expanding nitinol stents and early tests suggest that they perform mechanically as expected.
What is the design of the Zilver PTX trial?
The Zilver PTX RCT had a unique trial design. The RCT included a primary and secondary randomization, as well as an opportunity for patients in the PTA arm to cross over to treatment with Zilver PTX after experiencing a target lesion revascularization (TLR) in the first 12 months.
Why choose Zilver PTX for stents?
Only Zilver PTX combines an antiproliferative drug with efficient, polymer-free drug delivery and vessel support to demonstrate superior 5-year results against PTA and Zilver bare-metal stents. Short-term paclitaxel delivery in the SFA has been proven beneficial. Zilver PTX is the only polymer-free SFA drug-eluting stent.
Can Zilver PTX be used after target lesion revascularization (TLR)?
The RCT included a primary and secondary randomization, as well as an opportunity for patients in the PTA arm to cross over to treatment with Zilver PTX after experiencing a target lesion revascularization (TLR) in the first 12 months.
What is the mortality rate for Zilver PTX?
The all-cause mortality rate for the PTA/BMS group was 15.6% and 18.9% for the Zilver PTX group (p-value = 0.46). The addition of the new data confirmed no mortality signal for Zilver PTX.